Add BrightSurf on Google Email

Researchers uncover potential mechanism driving treatment resistance in common breast cancer

A study at the Garvan Institute of Medical Research found that inactivation of a stress pathway makes ER+ breast cancer cells ignore stress signals, allowing them to evade treatment. The JNK pathway acts as a cellular alarm system, and its disruption leads to treatment resistance.

SourceGarvan Institute of Medical Research·JournalJournal of Experimental & Clinical Cancer Research·TypeExperimental study·DateAug 18, 2025

Protective effects of Ejiao on chronic obstructive pulmonary disease in mice via modulation of the ER/AKT/NF-κB pathway

This study investigates the immunomodulatory effects of Ejiao on chronic obstructive pulmonary disease (COPD), focusing on its impact on inflammatory pathways and macrophages. Ejiao significantly improves lung function in COPD model mice, reduces inflammation, and modulates the ER/AKT/NF-κB pathway.

SourceXia & He Publishing Inc.·JournalFuture Integrative Medicine·DateMay 27, 2025

Preliminary study shows potential of Manuka honey as a nutraceutical for breast cancer

A new study by UCLA investigators found that Manuka honey contains compounds that can help reduce tumor growth in preclinical models. The research suggests that Manuka honey could potentially be developed into a natural supplement or standalone treatment for ER-positive breast cancer, which accounts for most breast cancer cases.

Estrogen receptor mutation study suggests potential treatments for endometrial cancers

Researchers at Huntsman Cancer Institute discovered that estrogen receptor mutations in endometrial cancers cause large changes in gene expression and cellular behavior. Inhibitors of CDK9, a protein that works with estrogen receptors, were found to be effective at reducing the growth and aggressiveness of endometrial cancer cells.

SourceHuntsman Cancer Institute·JournalMolecular Cancer Research·DateAug 21, 2023

Estrogen and PARP inhibitor combination for advanced ER+ breast cancer shows promise in preclinical models

A new study by researchers at Dartmouth Cancer Center shows that a combination of estrogen and PARP inhibitors can effectively treat advanced ER+ breast cancer by damaging cancer cells and preventing DNA repair. The treatment strategy has been shown to be effective regardless of BRCA1 or BRCA2 genetic mutations.

SourceDartmouth Health·JournalClinical Cancer Research·TypeExperimental study·DateJul 13, 2023

Updated findings on a new approach to ER-positive/HER2-negative breast cancer

The phase 1 and phase 2 studies showed that ARV-471 was well-tolerated and could promote substantial estrogen receptor degradation in patients with advanced disease. The study has led to a randomized phase 3 trial comparing ARV-471 with a SERD in patients with ER-positive/HER2-negative advanced breast cancer.

SourceUniversity of California - Los Angeles Health Sciences·TypeRandomized controlled/clinical trial·DateDec 7, 2022

New published data point to spike protein interactions with estrogen receptors as a cause for coagulopathy in COVID-19 patients, signaling sex effects and a path to improved vaccines

Researchers discovered a novel interaction between the SARS-CoV-2 Spike protein and human Estrogen Receptor Alpha, which may contribute to severe coagulopathy in COVID-19 patients. The study suggests that modulating ER signaling could mitigate rare vaccine side effects.

SourceDompe farmaceutici SpA·JournalScience Advances·TypeExperimental study·DateNov 30, 2022

Breast cancer patients with estrogen receptor mutations may benefit from early switch to fulvestrant/palbociclib

A recent study found that patients with hormone receptor-positive breast cancer who experience rising ESR1 mutations before disease progression can benefit from an early switch to fulvestrant plus palbociclib. This approach yields a statistically and clinically significant gain in progression-free survival, potentially justifying its a...

Elacestrant may improve outcomes for patients whose metastatic breast cancers progressed on prior endocrine therapy

In a phase III trial, elacestrant showed significant benefits in decreasing death or disease progression and increasing progression-free survival compared to standard of care. The treatment was well-tolerated with manageable side effects, offering hope for patients with ER-positive/HER2-negative metastatic breast cancer.

Newly approved PET imaging agent solves clinical dilemmas in breast cancer patients

A new PET imaging agent has been shown to solve 87% of diagnostic dilemmas in breast cancer patients, providing valuable information for personalized treatment decision-making. The agent's ability to visualize estrogen receptor expression across the body may improve patient outcomes and support broader implementation in clinical practice.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·TypeImaging analysis·DateSep 29, 2021

Fat-fighting drug discovery

A University of New Mexico Health Sciences Center-led research team has discovered a cancer-fighting compound that also reduces fat in obese mice. The team found that the compound, G-1, increases energy expenditure and targets brown fat cells, leading to weight loss and improved diabetes symptoms.

SourceUniversity of New Mexico Health Sciences Center·JournalScience Translational Medicine·DateFeb 6, 2020

Mayo researchers ID potential new treatment for one type of triple-negative breast cancer

Researchers have identified estradiol as a potential new treatment for triple-negative breast cancer with estrogen receptor beta expression, effectively inhibiting tumor growth in studies. Estradiol stimulates the expression of cystatins, which exhibit tumor-suppressing effects on neighboring and distant cancer cells.

SourceMayo Clinic·JournalProceedings of the National Academy of Sciences·DateOct 4, 2018

Team traces masculinization in mice to estrogen receptor in inhibitory neurons

Researchers at Cold Spring Harbor Laboratory have identified the specific hormone receptors and brain regions responsible for masculinization in mice. The study found that estrogen receptor alpha is essential in inhibitory neurons for male sexual and aggressive behaviors to emerge, while deleting it had no impact on excitatory neurons.

SourceCold Spring Harbor Laboratory·JournalHormones and Behavior·DateJul 19, 2017

Scripps scientists create innovative drug design strategy to improve breast cancer treatment

Researchers at Scripps Research Institute have developed a new structure-based drug design strategy to target the estrogen receptor, reducing resistance and side effects in hormone-driven breast cancer treatments. The approach uses x-ray crystallography to visualize how drugs interact with the receptor, allowing for the creation of bio...

SourceScripps Research Institute·JournalNature Chemical Biology·DateNov 21, 2016

Female hormone supplements with estrogen and progestin linked to breast cancer risk

Postmenopausal African American women who use female hormone supplements containing estrogen and progestin are at a 50% increased risk of estrogen receptor positive breast cancer. The study found greater increases in risk for recent and long-term users, highlighting the importance of limiting combination therapy.

SourceBoston University School of Medicine·JournalJNCI Journal of the National Cancer Institute·DateNov 30, 2015

Targeting estrogen receptors prevents binge eating in mice

A study published in JCI Journals suggests that estrogen replacement therapy can suppress binge-eating behaviors in mice. The effect required the presence of estrogen receptors in serotonin neurons, and direct delivery of an estrogen conjugate also reduced binge eating in these animals.

SourceJCI Journals·JournalJournal of Clinical Investigation·DateAug 26, 2014

New technology may help identify safe alternatives to BPA

Researchers have developed new tests to classify compounds' activity with great detail and speed, identifying safer replacements for BPA. The advance could offer a fast and cost-effective way to identify safe alternatives, as millions of tons of BPA and related compounds are produced each year.

SourceCell Press·JournalChemistry & Biology·DateMay 22, 2014

Continued research needed on treatment for women with lung cancer who are never smokers

A recent study found that lung cancer in women who have never smoked is more frequently associated with EGFR mutations and estrogen receptor (ER) overexpression. The researchers observed a higher percentage of these genetic abnormalities in patients who had not previously smoked, suggesting potential new treatment targets for this group.

SourceInternational Association for the Study of Lung Cancer·JournalJournal of Thoracic Oncology·DateJun 25, 2013

New sensors streamline detection of estrogenic compounds

Researchers have engineered new sensors that can detect estrogenic compounds in human cells, which is crucial for understanding the potential health risks associated with these substances. The sensors, developed by a team led by Huimin Zhao, were found to reliably detect estrogenic compounds within hours, even at low levels.

SourceUniversity of Illinois at Urbana-Champaign, News Bureau·JournalBiotechnology and Bioengineering·DateAug 25, 2011

Liver, dietary proteins key in fertility

A new study reveals that estrogen receptors in the liver are critical for maintaining fertility, with dietary protein playing a crucial role. The researchers found that mice on calorie-restricted diets showed reduced reproductive cycles, but those given more protein restored normal function.

SourceCell Press·JournalCell Metabolism·DateFeb 1, 2011